The invention relates to use of specific peptides derived from the cytotoxicity receptor NKp46 for preventing and treating diabetes, including type I diabetes (TID) and type 2 diabetes. The invention further relates to compositions comprising a fragment of the extracellular region of NKp46 for preventing the onset and progression of diabetes.

Original languageAmerican English
Patent numberEP3211002
IPCC07K 14/ 705 A I
Priority date14/03/13
StatePublished - 30 Aug 2017


Dive into the research topics of 'PEPTIDES DERIVED FROM THE ECTODOMAIN OF NKP46'. Together they form a unique fingerprint.

Cite this